High mobility group protein B1 is a predictor of poor survival in ovarian cancer

Lee Machado, Paul M Moseley, Robert Moss, Suha Deen, Christopher Nolan, Ian Spendlove, Judith Ramage

Research output: Contribution to JournalArticle

Abstract

High-mobility group protein B1 (HMGB1) has been implicated in numerous tumour types where expression regulates tumour cell growth and survival. We hypothesised that high HMGB1 expression in ovarian tumours would predict poor patient survival. Using tissue microarrays of primary ovarian cancers combined with a comprehensive database of clinicopathological variables, the expression of HMGB1 was assessed by immunohistochemistry in two independent cohorts (n=194 and n=360) using a monoclonal antibody specific for HMGB1. Kaplan-Meier analysis showed an association of HMGB1 expression with progression free survival in the primary cohort (p=0.023). In the validation cohort, expression was associated with overall survival (p=0.002). Low expression of HMGB1 was protective and in a multivariate model HMGB1 expression was shown to be an independent predictor of poor survival in ovarian cancer (p=0.006). The role of HMGB1 in cancer is complex. As high levels of HMGB1 expression are likely to render ovarian cancer cells resistant to chemotherapy, therapies targeting the HMGB1 axis may be appropriate in the treatment of ovarian cancer patients.
Original languageEnglish
Pages (from-to)101215-101223
Number of pages9
JournalOncotarget
Volume8
Issue number60
DOIs
Publication statusPublished - 24 Nov 2017

Keywords

  • DAMP
  • HMGB1
  • autophagy
  • ovarian cancer
  • prognostic

Fingerprint Dive into the research topics of 'High mobility group protein B1 is a predictor of poor survival in ovarian cancer'. Together they form a unique fingerprint.

  • Cite this

    Machado, L., Moseley, P. M., Moss, R., Deen, S., Nolan, C., Spendlove, I., & Ramage, J. (2017). High mobility group protein B1 is a predictor of poor survival in ovarian cancer. Oncotarget, 8(60), 101215-101223. https://doi.org/10.18632/oncotarget.20538